These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12842328)

  • 21. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
    J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2003 May; 168(1):107-13. PubMed ID: 12732393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project.
    De Socio GV; Bonfanti P; Ricci E; Orofino G; Madeddu G; Penco G; Gianelli E; Martinelli C; Carradori S; Quirino T; Rizzardini G;
    Biomed Pharmacother; 2008 Jan; 62(1):16-20. PubMed ID: 17851026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir.
    González de Requena D; Blanco F; Garcia-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Patient Care STDS; 2003 Sep; 17(9):443-5. PubMed ID: 14588081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.
    Shafran SD; Mashinter LD; Roberts SE
    HIV Med; 2005 Nov; 6(6):421-5. PubMed ID: 16268824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.
    Calza L; Manfredi R; Colangeli V; Pocaterra D; Rosseti N; Pavoni M; Chiodo F
    AIDS Patient Care STDS; 2009 Sep; 23(9):691-7. PubMed ID: 19739937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
    Valerio L; Fontas E; Pradier C; Lavrut T; Garraffo R; Dunais B; Cua E; Dellamonica P
    J Infect; 2005 Apr; 50(3):229-35. PubMed ID: 15780417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B; Resino S; Bellón JM; de José MI; Fortuny C; Navarro ML; Gurbindo MD; Ramos JT; Soler Palacín P; Léon JA; Asensi M; Mellado MJ; Muñoz-Fernández MA
    J Antimicrob Chemother; 2008 Jan; 61(1):183-90. PubMed ID: 18025025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dyslipidaemia in HIV-infected patients: association with adherence to potent antiretroviral therapy.
    Vergis EN; Paterson DL; Wagener MM; Swindells S; Singh N
    Int J STD AIDS; 2001 Jul; 12(7):463-8. PubMed ID: 11394983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avascular necrosis of the femoral head in a HIV-1 infected patient receiving lopinavir/ritonavir.
    Bongiovanni M; Chiesa E; Riva A; d'Arminio Monforte A; Bini T
    Int J Antimicrob Agents; 2003 Dec; 22(6):630-1. PubMed ID: 14659664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen.
    Loutfy MR; Ackad N; Antoniou T; Baril JG; Conway B; de Wet J; Trottier B; Kovacs CM; Thompson W; Martel AY; Trottier S; Rouleau D; Shafran SD; Rachlis A; Fraser C; Smaill F; Walmsley SL; Tseng AL; Sampalis JS
    HIV Clin Trials; 2007; 8(5):259-68. PubMed ID: 17956827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marked hyperlipidaemia on ritonavir therapy.
    Sullivan AK; Nelson MR
    AIDS; 1997 Jun; 11(7):938-9. PubMed ID: 9189227
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
    Bongiovanni M; Chiesa E; Di Biagio A; Meraviglia P; Capetti A; Tordato F; Cicconi P; Biasi P; Bini T; d'Arminio Monforte A
    J Antimicrob Chemother; 2005 Jun; 55(6):1003-7. PubMed ID: 15824089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hair loss induced by lopinavir-ritonavir.
    Borrás-Blasco J; Belda A; Rosique-Robles D; Casterá E; Abad J; Amorós-Quiles I
    Pharmacotherapy; 2007 Aug; 27(8):1215-8. PubMed ID: 17655521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
    Cohen C; Nieto-Cisneros L; Zala C; Fessel WJ; Gonzalez-Garcia J; Gladysz A; McGovern R; Adler E; McLaren C;
    Curr Med Res Opin; 2005 Oct; 21(10):1683-92. PubMed ID: 16238909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.